|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | T0\* | T3 | T6 | T9 | Last FU\* | *p value\** |
| OC | |  | | --- | | 41.5 | | (± 22.9) | | |  | | --- | | 13.5 | | (± 7.0) | | |  | | --- | | 9.9 | | (± 2.5) | | |  | | --- | | 6.8 | | (± 2.7) | | |  | | --- | | 6.7 | | (± 2.3) | | *p=0.0001* |
| BAP | |  | | --- | | 19.5 | | (± 4.9) | | |  | | --- | | 9.4 | | (± 0.75) | | |  | | --- | | 8.9 | | (± 0.48) | | |  | | --- | | 7.7 | | (± 0.99) | | |  | | --- | | 8.2 | | (± 0.68) | | *p=0.0001* |
| β-CTX | |  | | --- | | 0.498 | | (± 0.107) | | |  | | --- | | 0.034 | | (± 0.001) | | |  | | --- | | 0.033 | | (± 0.001) | | |  | | --- | | 0.033 | | (± 0.001) | | |  | | --- | | 0.084 | | (± 0.055) | | *p=0.0001* |

Supplemental Table 2. Bone turnovers markers trend (evaluated every three months) during denosumab treatment (a single 60 mg dose every six month). The p Value is referred to the difference between last follow-up value and basal value (T0). The values are represented by mean value and standard deviation.